News | December 17, 2024
SPARC signs LoI with UCSF and Tiller Therapeutics for pre-clinical oncology asset and associated IP
SPARC to receive 55% equity in Tiller Therapeutics
SPARC to receive 55% equity in Tiller Therapeutics
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
New PARTNER trial sub-study data show that post-operative ctDNA detection using tumour-informed MRD assays can accurately predict distant recurrence risk in triple-negative breast cancer patients
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Highlighting KEYTRUDA & expanding cancer pipeline
The summit will bring together 1,200+ delegates, 100+ international faculty from 25 countries
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
